Ovarian cancer(OC)is the deadliest gynecologic malignancy,with platinum-based chemotherapy,such as carboplatin,remaining the standard first-line treatment.However,resistance to carboplatin poses a major therapeutic ch...Ovarian cancer(OC)is the deadliest gynecologic malignancy,with platinum-based chemotherapy,such as carboplatin,remaining the standard first-line treatment.However,resistance to carboplatin poses a major therapeutic challenge,and its mechanisms are not fully understood.展开更多
基金supported by the US National Institutes of Health(No.1R01GM120156-01A1,R03CA223906-01,1R03CA283225-A1 to T.L.)the Kay Yow Cancer Fund(V Foundation for Cancer Research)(USA)(No.4486242 to T.L.)+1 种基金Showalter Scholar fund from Indiana University School of Medicine(USA)(No.2286263 to T.L.)the Indiana University Melvin and Bren Simon Comprehensive Cancer Center(IUSCCC)fund(USA)(No.2987664 to T.L.).
文摘Ovarian cancer(OC)is the deadliest gynecologic malignancy,with platinum-based chemotherapy,such as carboplatin,remaining the standard first-line treatment.However,resistance to carboplatin poses a major therapeutic challenge,and its mechanisms are not fully understood.
